Swiss real estate funds have experienced turbulent times over the past two years. However, the market environment has recently improved, and the asset class has stabilised, creating opportunities for investors. 

Demand for dairy alternatives has risen sharply in recent years. However, Swedish oat milk producer Oatly, which made a brilliant stock market debut in 2021, has so far been unable to capitalise on this. Meanwhile, traditional dairy companies such as Danone and Emmi are trying to position themselves in the market for plant-based milk alternatives.

The Swiss consumer goods giant appoints a new CEO to get the company back on track. Stock market reaction has been muted so far.

Individuals and businesses tend to avoid risk. For example, we can take out a property insurance to limit the damage in the event of a fire. Today, insurers are increasingly relying on their data pool to make the claims process more efficient. But the industry also faces challenges in dealing with new threats.

Cyber attacks and IT failures regularly hit the headlines. The most recent was over the summer, when an update from cybersecurity company Crowdstrike caused global outages and exposed the vulnerability of modern technology. The US company's shares have yet to recover.

In recent years, the range on offer in the freezer has changed considerably. Where the classic beef burger used to dominate, there are now alternatives made from pea protein, insects or even the meat-like mixture from Beyond Meat. But who is actually benefiting from this trend?

The market for weight-loss drugs is booming. Not only the pharmaceutical companies offering the medication are benefiting, but also their suppliers. Among them are the Swiss companies Bachem and Ypsomed.

Luxury seeks to sell exclusivity. At the same time, the industry wants to harness the purchasing power of the masses.

Global equity markets are plunging. In this environment, products with defensive features are in favour.

After a period of weakness, Roche shares are making a comeback. This makes the pharmaceutical giant the most valuable Swiss company, pushing Nestlé into second place.